NZ225158A - Pharmaceutical compositions in pellet form with enzymatically controlled release of an active - Google Patents

Pharmaceutical compositions in pellet form with enzymatically controlled release of an active

Info

Publication number: NZ225158A
Authority: NZ; New Zealand
Prior art keywords: enzyme; pharmaceutical composition; pharmaceutical; composition according; substrate
Prior art date: 1987-06-30

Application number

NZ225158A

Other languages

English (en)

Inventor

Horst-Georg Zerbe

Jorn Ullrich Becker

Original Assignee

Riker Laboratories Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-06-30

Filing date

1988-06-24

Publication date

1990-12-21

1988-06-24 Application filed by Riker Laboratories Inc filed Critical Riker Laboratories Inc

1990-12-21 Publication of NZ225158A publication Critical patent/NZ225158A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 32
239000008188 pellet Substances 0.000 title description 19
238000013270 controlled release Methods 0.000 title description 4
239000003814 drug Substances 0.000 claims description 46
108090000790 Enzymes Proteins 0.000 claims description 32
102000004190 Enzymes Human genes 0.000 claims description 32
229940088598 enzyme Drugs 0.000 claims description 32
239000000203 mixture Substances 0.000 claims description 30
239000000126 substance Substances 0.000 claims description 18
239000000758 substrate Substances 0.000 claims description 18
-1 phlean Polymers 0.000 claims description 14
229920000642 polymer Polymers 0.000 claims description 12
239000004382 Amylase Substances 0.000 claims description 10
229920002521 macromolecule Polymers 0.000 claims description 5
229920000856 Amylose Polymers 0.000 claims description 4
229920002678 cellulose Polymers 0.000 claims description 4
239000001913 cellulose Substances 0.000 claims description 4
108010010803 Gelatin Proteins 0.000 claims description 3
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 claims description 3
239000000945 filler Substances 0.000 claims description 3
229920000159 gelatin Polymers 0.000 claims description 3
239000008273 gelatin Substances 0.000 claims description 3
235000019322 gelatine Nutrition 0.000 claims description 3
235000011852 gelatine desserts Nutrition 0.000 claims description 3
239000011148 porous material Substances 0.000 claims description 3
DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 claims description 2
229920000945 Amylopectin Polymers 0.000 claims description 2
229920000018 Callose Polymers 0.000 claims description 2
108010059892 Cellulase Proteins 0.000 claims description 2
229920002101 Chitin Polymers 0.000 claims description 2
102000012286 Chitinases Human genes 0.000 claims description 2
108010022172 Chitinases Proteins 0.000 claims description 2
229920001661 Chitosan Polymers 0.000 claims description 2
229920000926 Galactomannan Polymers 0.000 claims description 2
229920002527 Glycogen Polymers 0.000 claims description 2
229920001202 Inulin Polymers 0.000 claims description 2
229920001543 Laminarin Polymers 0.000 claims description 2
239000005717 Laminarin Substances 0.000 claims description 2
229920000057 Mannan Polymers 0.000 claims description 2
108010054377 Mannosidases Proteins 0.000 claims description 2
102000001696 Mannosidases Human genes 0.000 claims description 2
108091005804 Peptidases Proteins 0.000 claims description 2
108010059820 Polygalacturonase Proteins 0.000 claims description 2
239000004365 Protease Substances 0.000 claims description 2
239000004373 Pullulan Substances 0.000 claims description 2
229920001218 Pullulan Polymers 0.000 claims description 2
102000006382 Ribonucleases Human genes 0.000 claims description 2
108010083644 Ribonucleases Proteins 0.000 claims description 2
108090000637 alpha-Amylases Proteins 0.000 claims description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
239000005018 casein Substances 0.000 claims description 2
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
235000021240 caseins Nutrition 0.000 claims description 2
229940106157 cellulase Drugs 0.000 claims description 2
108010093305 exopolygalacturonase Proteins 0.000 claims description 2
229940096919 glycogen Drugs 0.000 claims description 2
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
229940029339 inulin Drugs 0.000 claims description 2
235000019423 pullulan Nutrition 0.000 claims description 2
OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims 1
229920002984 Paramylon Polymers 0.000 claims 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical group CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
239000002775 capsule Substances 0.000 claims 1
229960002052 salbutamol Drugs 0.000 claims 1
150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
230000002496 gastric effect Effects 0.000 description 9
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 8
239000001863 hydroxypropyl cellulose Substances 0.000 description 8
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 8
239000001856 Ethyl cellulose Substances 0.000 description 7
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 7
235000019325 ethyl cellulose Nutrition 0.000 description 7
229920001249 ethyl cellulose Polymers 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
229920002261 Corn starch Polymers 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
239000008120 corn starch Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
239000000454 talc Substances 0.000 description 6
235000012222 talc Nutrition 0.000 description 6
229910052623 talc Inorganic materials 0.000 description 6
229920000881 Modified starch Polymers 0.000 description 5
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 5
229920001577 copolymer Polymers 0.000 description 5
210000001035 gastrointestinal tract Anatomy 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
239000008118 PEG 6000 Substances 0.000 description 4
235000011389 fruit/vegetable juice Nutrition 0.000 description 4
230000008855 peristalsis Effects 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
SMANXXCATUTDDT-UHFFFAOYSA-N Flunarizinum Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(CC=CC=2C=CC=CC=2)CC1 SMANXXCATUTDDT-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000013543 active substance Substances 0.000 description 3
BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
239000013078 crystal Substances 0.000 description 3
210000003736 gastrointestinal content Anatomy 0.000 description 3
230000003179 granulation Effects 0.000 description 3
238000005469 granulation Methods 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
125000005397 methacrylic acid ester group Chemical group 0.000 description 3
238000000034 method Methods 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 3
229960000278 theophylline Drugs 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
229920001800 Shellac Polymers 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000000654 additive Substances 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920002689 polyvinyl acetate Polymers 0.000 description 2
239000011118 polyvinyl acetate Substances 0.000 description 2
239000004208 shellac Substances 0.000 description 2
235000013874 shellac Nutrition 0.000 description 2
229940113147 shellac Drugs 0.000 description 2
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
229920003176 water-insoluble polymer Polymers 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
244000303965 Cyamopsis psoralioides Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
239000000219 Sympatholytic Substances 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
125000005396 acrylic acid ester group Chemical group 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
229920006318 anionic polymer Polymers 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000003356 anti-rheumatic effect Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
229940125716 antipyretic agent Drugs 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940097217 cardiac glycoside Drugs 0.000 description 1
239000002368 cardiac glycoside Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
239000003218 coronary vasodilator agent Substances 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
230000037406 food intake Effects 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
230000005176 gastrointestinal motility Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
DOIRQSBPFJWKBE-UHFFFAOYSA-N phthalic acid di-n-butyl ester Natural products CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000004089 psychotropic agent Substances 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000002048 spasmolytic effect Effects 0.000 description 1
229930002534 steroid glycoside Natural products 0.000 description 1
150000008143 steroidal glycosides Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000000948 sympatholitic effect Effects 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
229940064707 sympathomimetics Drugs 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000001993 wax Substances 0.000 description 1
229920001221 xylan Polymers 0.000 description 1
150000004823 xylans Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Botany (AREA)
Zoology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NZ225158A 1987-06-30 1988-06-24 Pharmaceutical compositions in pellet form with enzymatically controlled release of an active NZ225158A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19873721574 DE3721574A1 (de)	1987-06-30	1987-06-30	Arzneimittel in form von pellets mit enzymatisch kontrollierter arzneistoff-freisetzung

Publications (1)

Publication Number	Publication Date
NZ225158A true NZ225158A (en)	1990-12-21

Family

ID=6330589

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ225158A NZ225158A (en)	1987-06-30	1988-06-24	Pharmaceutical compositions in pellet form with enzymatically controlled release of an active

Country Status (7)

Country	Link
EP (1)	EP0370049A1 (xx)
JP (1)	JPH02504145A (xx)
AU (1)	AU618748B2 (xx)
DE (1)	DE3721574A1 (xx)
NZ (1)	NZ225158A (xx)
WO (1)	WO1989000045A1 (xx)
ZA (1)	ZA884622B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5049395A (en) *	1989-03-09	1991-09-17	Micro Vesicular Systems, Inc.	Controlled release vehicle
SE8901279D0 (sv) *	1989-04-10	1989-04-10	Pharmacia Ab	Komposition
DE3918801A1 (de) *	1989-06-06	1991-05-08	Schmidt Walter	Praeparat zur geregelten wirkstoffabgabe und verfahren zu dessen herstellung
US5252318A (en) *	1990-06-15	1993-10-12	Allergan, Inc.	Reversible gelation compositions and methods of use
US5603956A (en) *	1990-11-27	1997-02-18	Labopharm Inc.	Cross-linked enzymatically controlled drug release
NL9201195A (nl) *	1992-07-03	1994-02-01	Tno	Preparaat voor de gereguleerde afgifte van een werkzame stof en werkwijze ter bereiding van een dergelijk preparaat.
NL9201196A (nl) *	1992-07-03	1994-02-01	Tno	Preparaat voor de gereguleerde afgifte van een werkzame stof en werkwijze ter bereiding van een dergelijk preparaat.
EP0651634B1 (en) *	1992-07-24	1996-05-08	Labopharm Inc.	Cross-linked polyhydroxylic material for enzymatically controlled drug release
BR9307797A (pt) *	1992-12-28	1995-11-14	Bausch & Lomb	Composição e processo para retardar a liberação de uma composição neutralizante a uma solução de peróxide de hidrogenio para desinfetar lentes de contato
CA2378265C (en) *	1999-08-09	2007-11-20	Dainippon Pharmaceutical Co., Ltd.	Solid preparations containing chitosan powder and process for producing the same
WO2001037811A1 (en) *	1999-11-22	2001-05-31	Akzo Nobel N.V.	Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
FR2938433B1 (fr) *	2008-11-19	2011-09-09	Francois Fauran	Compositions pharmaceutiques utilisant l'inuline comme excipient de granulation
JP6069782B2 (ja) *	2012-11-09	2017-02-01	国立大学法人佐賀大学	基質応答性自律振動型マイクロカプセル
CN113172887B (zh) *	2021-03-15	2023-04-07	中国科学院上海硅酸盐研究所	一种具有缓释功能的同轴支架材料

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3493652A (en) *	1962-09-14	1970-02-03	Charles W Hartman	Controlled release medicament
US3977404A (en) *	1975-09-08	1976-08-31	Alza Corporation	Osmotic device having microporous reservoir
US4261969A (en) *	1979-05-03	1981-04-14	World Health Organization	Controlled drug release composition
DE2923279C2 (de) *	1979-06-08	1987-07-09	Kali-Chemie Pharma Gmbh, 3000 Hannover	Verfahren zur Herstellung von Pankreatin-Pellets und diese enthaltende Arzneimittel
JPS5640151A (en) *	1979-09-06	1981-04-16	Daiichi Seiyaku Co	Coating device for tablet
WO1983003061A1 (en) *	1982-03-04	1983-09-15	Battelle Development Corp	Dual microcapsules
US4609374A (en) *	1985-04-22	1986-09-02	Alza Corporation	Osmotic device comprising means for governing initial time of agent release therefrom

1987
- 1987-06-30 DE DE19873721574 patent/DE3721574A1/de not_active Withdrawn
1988
- 1988-06-23 JP JP88506264A patent/JPH02504145A/ja active Pending
- 1988-06-23 EP EP88906543A patent/EP0370049A1/en not_active Withdrawn
- 1988-06-23 AU AU21245/88A patent/AU618748B2/en not_active Ceased
- 1988-06-23 WO PCT/US1988/002131 patent/WO1989000045A1/en not_active Ceased
- 1988-06-24 NZ NZ225158A patent/NZ225158A/en unknown
- 1988-06-28 ZA ZA884622A patent/ZA884622B/xx unknown

Also Published As

Publication number	Publication date
ZA884622B (en)	1990-02-28
AU618748B2 (en)	1992-01-09
JPH02504145A (ja)	1990-11-29
DE3721574A1 (de)	1989-01-12
WO1989000045A1 (en)	1989-01-12
EP0370049A1 (en)	1990-05-30
AU2124588A (en)	1989-01-30

Publication	Publication Date	Title
JP4749639B2 (ja)	2011-08-17	味がマスクされ、活性成分を即時放出する、被覆された顆粒の製造方法
US6413494B1 (en)	2002-07-02	Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides
US6312728B1 (en)	2001-11-06	Sustained release pharmaceutical preparation
US5422121A (en)	1995-06-06	Oral dosage unit form
EP0305918B1 (en)	1992-12-16	Controlled release delivery coating formulation for bioactive substances
US5294448A (en)	1994-03-15	Delayed release formulations
JP3806740B2 (ja)	2006-08-09	薬剤運搬組成物
US6068859A (en)	2000-05-30	Controlled-release dosage forms of Azithromycin
JP2773959B2 (ja)	1998-07-09	大腸内放出性固形製剤
US5540945A (en)	1996-07-30	Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
NZ225158A (en)	1990-12-21	Pharmaceutical compositions in pellet form with enzymatically controlled release of an active
US20030161874A1 (en)	2003-08-28	Controlled release oral dosage form
US20020160046A1 (en)	2002-10-31	Delivery system for omeprazole and its salts
JP2001527023A (ja)	2001-12-25	胃で保持するのに適合した長期放出性活性剤剤形
JP2012506850A (ja)	2012-03-22	結腸ターゲッティング用の水不溶性ポリマー：デンプン系フィルムコーティング
US5776489A (en)	1998-07-07	Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form
EP0264989B1 (en)	1991-12-18	Galenic formulations for oral use of rhein derivatives with delayed release for therapeutical use
EP1109535B1 (en)	2004-07-28	Extended release acetaminophen
US4954349A (en)	1990-09-04	Oral magnesium and potassium compositions and use
GB2209668A (en)	1989-05-24	Oral magnesium and potassium compositions
EP0540813A1 (en)	1993-05-12	Sustained release formulations of acetazolamide
CA2634006C (en)	2013-07-30	Pharmaceutical sustained release compositions comprising liothyronine or the sodium salt of liothyronine
CA2685214A1 (en)	2002-08-15	Improved controlled release oral dosage form
JP3456211B2 (ja)	2003-10-14	持続性製剤
JPS6299322A (ja)	1987-05-08	硬カプセル剤の新しい剤形